Planet Neuron: Start-Ups in Neurobiology
This article was originally published in Start Up
Executive Summary
New drug discovery tools promise to shorten the distance between mouse and man while new neurology drugs remain on the distant horizon. Meanwhile, licensing keeps start-ups going.
You may also be interested in...
Neurotrophic Bioscience Inc.
Despite setbacks by neuroscience companies Cephalon Inc. and Regeneron Pharmaceuticals Inc., the hope that neurotrophic factors will provide relief for millions of sufferers of neurodegenerative diseases, by slowing the progression of the disease, is alive and kicking. Neurotrophic Biosciences hopes to succeed where others have not by taking an approach that will apply combinations of highly specific neurotrophic factors, many of them newly discovered, to the treatment of neurodegenerative diseases.
Antalium Inc.
In recent years, insights into the molecular biology of pain have given drug developers new targets, and companies are thronging to the field in the hope of developing side-effect free, non-narcotic analgesics. With the aim of developing novel drugs for pain based on novel ion channels, McGill University has spun-off Antalium Inc.
Neurotech SA
Neurotech is making use of the angiogenic properties of tumors to eradicate them. Beyond brain tumors, Neurotech is targeting other conditions where angiogenesis is important, for example, ischemic stroke. Neuortech's approach is also suited to a variety of other neurological disorders, including Alzheimer's disease and Parkinson's disease.